Home › Funds › ELKHORN PARTNERS LIMITED PARTNERSHIP › CRSP
ELKHORN PARTNERS LIMITED PARTNERSHIP position in CRSP
CRISPR THERAPEUTICS AG · Health Care
ELKHORN PARTNERS LIMITED PARTNERSHIP reported holding 1,600 shares of CRSP (CRISPR THERAPEUTICS AG) in its Q3 2026 13F filing — a position valued at US$89K, representing 0.08% of its reported portfolio and ranking #34 among its reported holdings. ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed CRSP holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How ELKHORN PARTNERS LIMITED PARTNERSHIP's CRSP position evolved
ELKHORN PARTNERS LIMITED PARTNERSHIP first disclosed a stake in CRSP in Q3 2023 at 250 shares (US$11K). The position peaked in Q2 2025 at 4,000 shares, worth US$195K. Across 11 filings, ELKHORN PARTNERS LIMITED PARTNERSHIP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,600 shares valued at US$89K — a reduction of -400 shares quarter over quarter.. Notable position changes include a 210% increase in Q3 2024 (shares fell 16% over the following quarter), a 45% trim in Q3 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 250 | $11.00K | New |
| Q2 2024 | 1.00K | $54.00K | New |
| Q3 2024 | 3.10K | $146.00K | Add |
| Q4 2024 | 3.80K | $150.00K | Add |
| Q1 2025 | 4.20K | $143.00K | Add |
| Q2 2025 | 4.00K | $194.56K | Reduce |
| Q3 2025 | 2.20K | $142.58K | Reduce |
| Q4 2025 | 1.66K | $87.05K | Reduce |
| Q1 2026 | 1.90K | $90.38K | Add |
| Q2 2026 | 2.00K | $109.08K | Add |
| Q3 2026 | 1.60K | $88.51K | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRSP and 13F data
CRSP (CRISPR THERAPEUTICS AG) is a Health Care company. 30 other funds we track also report a position in CRSP — the largest reported positions include ARK Invest (US$556.3M), Orbis Allan Gray Ltd (US$297.2M), GSK plc (US$144.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRSP
- ARK Invest 10.06M sh · $556.34M · Q3 2026
- Orbis Allan Gray Ltd 5.45M sh · $297.20M · Q2 2026
- GSK plc 2.61M sh · $144.30M · Q3 2026
- SR ONE CAPITAL MANAGEMENT, LP 2.04M sh · $111.19M · Q2 2026
- Amova Asset Management Americas, Inc. 1.45M sh · $80.36M · Q3 2026
- EcoR1 Capital, LLC 1.39M sh · $75.77M · Q2 2026
- NEA Management Company, LLC 1.06M sh · $57.73M · Q2 2026
More on ELKHORN PARTNERS LIMITED PARTNERSHIP
FAQ
How long has ELKHORN PARTNERS LIMITED PARTNERSHIP held CRSP?
ELKHORN PARTNERS LIMITED PARTNERSHIP has disclosed CRSP holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is ELKHORN PARTNERS LIMITED PARTNERSHIP's current position in CRSP?
As of Q3 2026, ELKHORN PARTNERS LIMITED PARTNERSHIP holds 1.60K shares of CRSP (CRISPR THERAPEUTICS AG), valued at $88.51K, representing 0.08% of its reported portfolio and ranking #34.
Has ELKHORN PARTNERS LIMITED PARTNERSHIP been buying or selling CRSP?
In the latest 13F filing (Q3 2026), ELKHORN PARTNERS LIMITED PARTNERSHIP reduced its position in CRSP. The position peaked in Q2 2025 at 4.00K shares.
Which other funds hold CRSP?
Other major institutional holders of CRSP include ARK Invest, Orbis Allan Gray Ltd, GSK plc, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.